This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pilot Study on MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2008 by Scil Technology GmbH.
Recruitment status was:  Active, not recruiting
FGK Clinical Research GmbH
Information provided by:
Scil Technology GmbH Identifier:
First received: August 21, 2007
Last updated: April 21, 2008
Last verified: April 2008
The purpose of the study is to gain experience of safety and efficacy with MD05 in man in alveolar bone regeneration.

Condition Intervention Phase
Alveolar Bone Loss Periodontal Bone Loss Drug: MD05 and open flap debridement Procedure: Open flap debridement Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects

Further study details as provided by Scil Technology GmbH:

Primary Outcome Measures:
  • Evidence of regeneration of alveolar bone. [ Time Frame: October 2008 ]

Secondary Outcome Measures:
  • Evidence of uncompromised healing. [ Time Frame: October 2008 ]

Estimated Enrollment: 20
Study Start Date: July 2007
Estimated Study Completion Date: November 2008
Estimated Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Open flap debridement + MD05
Drug: MD05 and open flap debridement
recombinant human GDF-5 coated onto ß-tricalcium phosphate
Active Comparator: 2
Open flap debridement
Procedure: Open flap debridement
Open flap debridement alone


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients requiring extraction of teeth with advanced intrabony periodontal defects at single rooted teeth without root concavities/furrows located in the maxilla and mandible (maxillary/mandibular premolars, maxillary incisors; presurgery probing depth ≥ 6 mm, intrasurgery defect depth ≥ 4 mm) or located the mesial or distal aspect of mandibular molar teeth without adjacent teeth (excluding defects also involving the furcation area).
  • Teeth to be treated must be scheduled for extraction in a treatment plan established by clinicians unrelated to the study.
  • Male and female patients, aged 18 - 75 years
  • Patients must be non-smokers
  • Female patients must be infertile (either sterilized or postmenopausal). If a patient's menopausal status at screening is uncertain, levels of follicle stimulating hormone (FSH) should be determined. Patients with an FSH level > 25 IU/l and absence of menstrual bleeding > 6 months will satisfy the definition of postmenopausal status.
  • Patient must provide written informed consent

Exclusion Criteria:

  • Women of childbearing potential, pregnant or lactating women
  • Participation in another clinical study within 30 days prior to study start
  • Previous participation in this study
  • Legal incompetence or restricted legal competence
  • Alcoholism, drug dependency, smoking
  • Acute or chronic infection at the application site
  • Known infection with HIV, HBV, or HCV
  • Severe allergic rhinitis which requires permanent medication
  • Known intolerance of or hypersensitivity to ß-TCP or rhGDF?5
  • Presence of local or systemic malignant disease or history of local or systemic malignant disease in the past 5 years.
  • Patients requiring chemo- or radiotherapy
  • Previous or current radiotherapy of the head
  • Chronic liver disorder (AST and/or ALT over 2 times upper limit of normal)
  • Impaired renal function (creatinine over 1.5 times upper limit of normal)
  • Uncontrolled insulin-dependent diabetes mellitus (HbA1c > 7%)
  • Clinically relevant symptoms of thyroid dysfunction
  • Severe hypertension (RRdiast > 110 mmHg)
  • Clinically relevant cardiovascular disease e.g., decompensated cardiac insufficiency, hemodynamically relevant heart valve defects, or myocardial infarction during the last three months
  • Systemic bone disease or illness having influence in bone metabolism (e.g. Osteogenesis imperfecta, Paget's disease, Ehlers-Danlos disease, osteomalacia, renal osteodystrophia, hyperparathyroidism)
  • Clinically relevant blood coagulation disorder
  • Leukopenia < 3.500 leukocytes/µL
  • Previous (within last 2 months before screening visit) or current treatment with systemic corticosteroids of more than 5 mg/day prednisone equivalent
  • Previous or current therapy with drugs having any influence on bone metabolism such as calcitonin or parathormone (as teriparatid) within the last 6 months before screening visit, bisphosphonates or fluoride at least for 30 days within the last 12 months before screening visit
  • Previous (within last 2 months before screening visit) or current treatment with immunosuppressant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00519155

Department of Periodontology, Semmelweis University Budapest
Budapest, Hungary, 1085
Sponsors and Collaborators
Scil Technology GmbH
FGK Clinical Research GmbH
Principal Investigator: Anton Sculean, Prof. Department of Periodontology; Radboud University Medical Center
  More Information

Responsible Party: Björn Capsius, Scil Technology GmbH Identifier: NCT00519155     History of Changes
Other Study ID Numbers: Scil-MD05-C02
EudraCT-No.: 2006-005883-25
Study First Received: August 21, 2007
Last Updated: April 21, 2008

Additional relevant MeSH terms:
Alveolar Bone Loss
Bone Resorption
Bone Diseases
Musculoskeletal Diseases
Periodontal Atrophy
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases processed this record on September 19, 2017